Shanghai Bio-heart Biological Technology Co (HKSE:02185) Total Receivables: HK$21.72 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02185 Shanghai Bio-heart Biological Technology Co Ltd HKSE:02185
28 GF Score
Price HK$2.31
! 3 Warning Signs
View Full Analysis

What is Shanghai Bio-heart Biological Technology Co Total Receivables?

Shanghai Bio-heart Biological Technology Co HKSE:02185 -2.33% 28 Total Receivables is HK$21.72 Mil as of Dec. 2025. GuruFocus rates HKSE:02185 with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Shanghai Bio-heart Biological Technology Co's Total Receivables for the quarter that ended in Dec. 2025 was HK$21.72 Mil.

Shanghai Bio-heart Biological Technology Co Total Receivables Related Terms

Shanghai Bio-heart Biological Technology Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Shanghai Bio-heart Biological Technology Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Bio-heart Biological Technology Co Total Receivables Chart

Shanghai Bio-heart Biological Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 21.72

Shanghai Bio-heart Biological Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 13.30 21.72
HKSE:02185
28GF Score
Shanghai Bio-heart Biological Technology Co Ltd HKSE:02185
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Bio-heart Biological Technology Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$21.72 Mil mean?
Shanghai Bio-heart Biological Technology Co (HKSE:02185) has a Total Receivables of HK$21.72 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Shanghai Bio-heart Biological Technology Co and its competitors.
Is Shanghai Bio-heart Biological Technology Co's Total Receivables too high?
Shanghai Bio-heart Biological Technology Co's current Total Receivables is HK$21.72 Mil. Overall, Shanghai Bio-heart Biological Technology Co has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Bio-heart Biological Technology Co's Total Receivables compare to VRTX and REGN?
Shanghai Bio-heart Biological Technology Co's Total Receivables of HK$21.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Shanghai Bio-heart Biological Technology Co and its competitors. Shanghai Bio-heart Biological Technology Co's current Total Receivables is HK$21.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Bio-heart Biological Technology Co stock overvalued right now?
Shanghai Bio-heart Biological Technology Co (HKSE:02185) has a current Total Receivables of HK$21.72 Mil. The current Total Receivables is HK$21.72 Mil. Shanghai Bio-heart Biological Technology Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Shanghai Bio-heart Biological Technology Co (HKSE:02185), the current Total Receivables is HK$21.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shanghai Bio-heart Biological Technology Co Business Description

Address No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension. Currently, the portfolio has three product candidates in various stages of clinical development.
28GF Score

Get the complete analysis for HKSE:02185

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.31
Price